Incannex Healthcare Limited Sponsored ADR (IXHL)
NASDAQ:IXHL
IXHL Stock Chart & Stats
$0.39
-$0.11(-5.37%)
At close: 4:00 PM EST
$0.39
-$0.11(-5.37%)
Day’s Range― - ―
52-Week Range$2.40 - $49.80
Previous CloseN/A
Volume10.98K
Average Volume (3M)585.60K
Market Cap
$40.73M
Enterprise Value-$29.57M
Total Cash (Recent Filing)$68.90M
Total Debt (Recent Filing)$163.00K
Price to Earnings (P/E)―
Beta4.01
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.60
Shares Outstanding11,944,312
10 Day Avg. Volume969,524
30 Day Avg. Volume585,598
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.55
Price to Sales (P/S)86.40
P/FCF Ratio-0.59
Enterprise Value/Market Cap-0.73
Enterprise Value/Revenue-443.95
Enterprise Value/Gross Profit-443.95
Enterprise Value/Ebitda0.65
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.2
Revenue Forecast (FY)$700.00K
Bulls Say, Bears Say
Bulls Say
Strong Cash Position, No DebtA ~$75M cash balance with zero debt materially extends runway to fund DReAMzz Phase 2 and a planned Phase 3, reducing near-term financing pressure. This durable liquidity cushion supports clinical execution and lowers short-term solvency risk across the next 12–24 months.
Low Leverage And Growing EquityA conservative capital structure with minimal debt and growing equity increases financial flexibility to fund trials, negotiate partnerships, and absorb clinical setbacks. Lower fixed obligations reduce default risk and preserve strategic optionality for multi-stage development plans.
Clinical Progress And Regulatory SupportPositive Phase 2 data plus Fast Track designation materially raise the probability of efficient late-stage development for IHL-42X. Combined with structured dose-optimization and external advisory engagement, this improves long-term chances of approval and eventual commercialization in an underserved market.
Bears Say
Persistent Negative Cash FlowContinued negative operating and free cash flow (≈-$12.5M in 2025) signals structural cash burn that will require future funding or drawdown of reserves. Even with improved liquidity, persistent burn constrains optionality and risks dilution if capital markets tighten or milestones slip.
Ongoing Heavy Losses, No ProfitabilitySustained negative margins and large net losses indicate capital is not yet producing returns and the company lacks an earnings pathway until successful commercialization. This structural lack of profitability increases reliance on external financing and heightens investor dilution risk over the medium term.
Clinical-stage Concentration And Binary RiskBusiness is concentrated in a small number of clinical-stage programs, making long-term outcomes highly binary. Regulatory, enrollment or efficacy setbacks on lead programs would materially impact value and cash runway, an inherent structural risk for companies without marketed products.
Incannex Healthcare Limited Sponsored ADR News
IXHL FAQ
What was Incannex Healthcare Limited Sponsored ADR’s price range in the past 12 months?
Incannex Healthcare Limited Sponsored ADR lowest stock price was $2.40 and its highest was $49.80 in the past 12 months.
What is Incannex Healthcare Limited Sponsored ADR’s market cap?
Incannex Healthcare Limited Sponsored ADR’s market cap is $40.73M.
When is Incannex Healthcare Limited Sponsored ADR’s upcoming earnings report date?
Incannex Healthcare Limited Sponsored ADR’s upcoming earnings report date is Sep 02, 2026 which is in 159 days.
How were Incannex Healthcare Limited Sponsored ADR’s earnings last quarter?
Incannex Healthcare Limited Sponsored ADR released its earnings results on Mar 02, 2026. The company reported -$0.6 earnings per share for the quarter, the consensus estimate of -$0.6 by $0.
Is Incannex Healthcare Limited Sponsored ADR overvalued?
According to Wall Street analysts Incannex Healthcare Limited Sponsored ADR’s price is currently Overvalued.
Does Incannex Healthcare Limited Sponsored ADR pay dividends?
Incannex Healthcare Limited Sponsored ADR does not currently pay dividends.
What is Incannex Healthcare Limited Sponsored ADR’s EPS estimate?
Incannex Healthcare Limited Sponsored ADR’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Incannex Healthcare Limited Sponsored ADR have?
Incannex Healthcare Limited Sponsored ADR has 11,944,312 shares outstanding.
What happened to Incannex Healthcare Limited Sponsored ADR’s price movement after its last earnings report?
Incannex Healthcare Limited Sponsored ADR reported an EPS of -$0.6 in its last earnings report, expectations of -$0.6. Following the earnings report the stock price went down -9.906%.
Which hedge fund is a major shareholder of Incannex Healthcare Limited Sponsored ADR?
Currently, no hedge funds are holding shares in IXHL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Incannex Healthcare Limited Sponsored ADR Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
IXHL Sentiment 70%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.8%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-85.39%
12-Months-Change
Fundamentals
Return on Equity
-199.09%
Trailing 12-Months
Asset Growth
575.36%
Trailing 12-Months
Company Description
Incannex Healthcare Limited Sponsored ADR
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea; and Monash Trauma Group at the Department of Neuroscience, Monash University to conduct a study on the protective effect of IHL-216A in sports concussion. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Sydney, Australia.
Technical Analysis
Assertio Therapeutics
―
Cumberland Pharmaceuticals
―
China SXT Pharmaceuticals
―
Journey Medical Corp
―
BioAge Labs, Inc.
―